Cargando…

Concurrent Infection of Hepatitis B Virus Negatively Affects the Clinical Outcome and Prognosis of Patients with Non-Hodgkin’s Lymphoma after Chemotherapy

Hepatitis B virus (HBV) is hepatotropic and lymphotropic. HBV-infected individuals have an increased risk of developing malignant lymphoma, and the HBV infection rate in lymphoma patients is significantly higher than that in the general population. However, the exact mechanism and correlation betwee...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Jie, Wang, Jianmin, Yang, Jianmin, Zhang, Weiping, Song, Xianmin, Chen, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3704665/
https://www.ncbi.nlm.nih.gov/pubmed/23861969
http://dx.doi.org/10.1371/journal.pone.0069400
_version_ 1782276063910428672
author Chen, Jie
Wang, Jianmin
Yang, Jianmin
Zhang, Weiping
Song, Xianmin
Chen, Li
author_facet Chen, Jie
Wang, Jianmin
Yang, Jianmin
Zhang, Weiping
Song, Xianmin
Chen, Li
author_sort Chen, Jie
collection PubMed
description Hepatitis B virus (HBV) is hepatotropic and lymphotropic. HBV-infected individuals have an increased risk of developing malignant lymphoma, and the HBV infection rate in lymphoma patients is significantly higher than that in the general population. However, the exact mechanism and correlation between HBV infection and lymphoma onset and progression currently remain unclear. We retrospectively analyzed clinical data from non-Hodgkin’s lymphoma (NHL) patients with different HBV infection statuses. The results showed that the HBV infection rate was significantly higher in patients with B-cell type and late stage of NHL. The chemotherapy efficacy for NHL patients with chronic active HBV infection was significantly lower than that for the patients with chronic inactive HBV infection, the patients with HBV carriers and the patients without HBV infection. In addition, the NHL chemotherapy activated HBV replication and caused significant liver dysfunction, which could further reduce the chemotherapy efficacy. Through Kaplan-Meier survival curve and log-rank analysis, we found that the HBV infection status in NHL patients was significantly correlated with the patients’ progression-free survival (PFS) and overall survival (OS). Compared with the patients without HBV infection (PFS: 95% CI 47.915 to 55.640; OS: 95% CI 81.324 to 86.858), the PFS and OS of the patients with chronic active HBV infection were significantly shorter (PFS: 95% CI 9.424 to 42.589, P < 0.001; OS: 95% CI 42.840 to 82.259, P = 0.006). The study demonstrated that the sustained HBV replication in patients with chronic active HBV infection could be a key factor that influences the prognosis of NHL patients after chemotherapy, and thus may provide information for designing rational clinical treatments for NHL patients with different HBV infection statuses and improve the treatment efficacy and prognosis.
format Online
Article
Text
id pubmed-3704665
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-37046652013-07-16 Concurrent Infection of Hepatitis B Virus Negatively Affects the Clinical Outcome and Prognosis of Patients with Non-Hodgkin’s Lymphoma after Chemotherapy Chen, Jie Wang, Jianmin Yang, Jianmin Zhang, Weiping Song, Xianmin Chen, Li PLoS One Research Article Hepatitis B virus (HBV) is hepatotropic and lymphotropic. HBV-infected individuals have an increased risk of developing malignant lymphoma, and the HBV infection rate in lymphoma patients is significantly higher than that in the general population. However, the exact mechanism and correlation between HBV infection and lymphoma onset and progression currently remain unclear. We retrospectively analyzed clinical data from non-Hodgkin’s lymphoma (NHL) patients with different HBV infection statuses. The results showed that the HBV infection rate was significantly higher in patients with B-cell type and late stage of NHL. The chemotherapy efficacy for NHL patients with chronic active HBV infection was significantly lower than that for the patients with chronic inactive HBV infection, the patients with HBV carriers and the patients without HBV infection. In addition, the NHL chemotherapy activated HBV replication and caused significant liver dysfunction, which could further reduce the chemotherapy efficacy. Through Kaplan-Meier survival curve and log-rank analysis, we found that the HBV infection status in NHL patients was significantly correlated with the patients’ progression-free survival (PFS) and overall survival (OS). Compared with the patients without HBV infection (PFS: 95% CI 47.915 to 55.640; OS: 95% CI 81.324 to 86.858), the PFS and OS of the patients with chronic active HBV infection were significantly shorter (PFS: 95% CI 9.424 to 42.589, P < 0.001; OS: 95% CI 42.840 to 82.259, P = 0.006). The study demonstrated that the sustained HBV replication in patients with chronic active HBV infection could be a key factor that influences the prognosis of NHL patients after chemotherapy, and thus may provide information for designing rational clinical treatments for NHL patients with different HBV infection statuses and improve the treatment efficacy and prognosis. Public Library of Science 2013-07-08 /pmc/articles/PMC3704665/ /pubmed/23861969 http://dx.doi.org/10.1371/journal.pone.0069400 Text en © 2013 Chen et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Chen, Jie
Wang, Jianmin
Yang, Jianmin
Zhang, Weiping
Song, Xianmin
Chen, Li
Concurrent Infection of Hepatitis B Virus Negatively Affects the Clinical Outcome and Prognosis of Patients with Non-Hodgkin’s Lymphoma after Chemotherapy
title Concurrent Infection of Hepatitis B Virus Negatively Affects the Clinical Outcome and Prognosis of Patients with Non-Hodgkin’s Lymphoma after Chemotherapy
title_full Concurrent Infection of Hepatitis B Virus Negatively Affects the Clinical Outcome and Prognosis of Patients with Non-Hodgkin’s Lymphoma after Chemotherapy
title_fullStr Concurrent Infection of Hepatitis B Virus Negatively Affects the Clinical Outcome and Prognosis of Patients with Non-Hodgkin’s Lymphoma after Chemotherapy
title_full_unstemmed Concurrent Infection of Hepatitis B Virus Negatively Affects the Clinical Outcome and Prognosis of Patients with Non-Hodgkin’s Lymphoma after Chemotherapy
title_short Concurrent Infection of Hepatitis B Virus Negatively Affects the Clinical Outcome and Prognosis of Patients with Non-Hodgkin’s Lymphoma after Chemotherapy
title_sort concurrent infection of hepatitis b virus negatively affects the clinical outcome and prognosis of patients with non-hodgkin’s lymphoma after chemotherapy
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3704665/
https://www.ncbi.nlm.nih.gov/pubmed/23861969
http://dx.doi.org/10.1371/journal.pone.0069400
work_keys_str_mv AT chenjie concurrentinfectionofhepatitisbvirusnegativelyaffectstheclinicaloutcomeandprognosisofpatientswithnonhodgkinslymphomaafterchemotherapy
AT wangjianmin concurrentinfectionofhepatitisbvirusnegativelyaffectstheclinicaloutcomeandprognosisofpatientswithnonhodgkinslymphomaafterchemotherapy
AT yangjianmin concurrentinfectionofhepatitisbvirusnegativelyaffectstheclinicaloutcomeandprognosisofpatientswithnonhodgkinslymphomaafterchemotherapy
AT zhangweiping concurrentinfectionofhepatitisbvirusnegativelyaffectstheclinicaloutcomeandprognosisofpatientswithnonhodgkinslymphomaafterchemotherapy
AT songxianmin concurrentinfectionofhepatitisbvirusnegativelyaffectstheclinicaloutcomeandprognosisofpatientswithnonhodgkinslymphomaafterchemotherapy
AT chenli concurrentinfectionofhepatitisbvirusnegativelyaffectstheclinicaloutcomeandprognosisofpatientswithnonhodgkinslymphomaafterchemotherapy